2005 Vol. 29, No. 5
Display Method:
2005, 29(5): 193-196.
[PDF 171KB]
Abstract:
2005, 29(5): 197-200.
Abstract:
PET scanning has a definite clinical impact on diagnosis, initial staging, restaging, monitoring therapeutic effects of malignancies, and on assessment of myocardial viability. Whereas, PET scans has false positive diagnosis and false negative diagnosis of malignant lesions, It leads to reduce specifity in PET imaging. Application of diagnostic CT, especially applying contrast enhanced CT scans, three dimensional technique, CTA(CT angiography), CT perfusion and CT virtual endoscopy can realize dominance complementation with PET and CT, PET-CT imaging diagnosis combines with PET and CT diagnostic technique, It improves sensitivity, specifity, and accuracy in clinical application of PET-CT scanner.
PET scanning has a definite clinical impact on diagnosis, initial staging, restaging, monitoring therapeutic effects of malignancies, and on assessment of myocardial viability. Whereas, PET scans has false positive diagnosis and false negative diagnosis of malignant lesions, It leads to reduce specifity in PET imaging. Application of diagnostic CT, especially applying contrast enhanced CT scans, three dimensional technique, CTA(CT angiography), CT perfusion and CT virtual endoscopy can realize dominance complementation with PET and CT, PET-CT imaging diagnosis combines with PET and CT diagnostic technique, It improves sensitivity, specifity, and accuracy in clinical application of PET-CT scanner.
2005, 29(5): 201-205.
Abstract:
PET-CT realized the image fusion of PET and CT in one single machine. But some technical reasons such as X-ray-based attenuation correction and nonsimuhaneous acquisition between PET and CT lead to some PET-CT artifacts which interrupt the image interpretation and may cause false-positive or falsenegative diagnosis. This review will talk about these artifacts, analyze the causes and discuss the possible preventive measures.
PET-CT realized the image fusion of PET and CT in one single machine. But some technical reasons such as X-ray-based attenuation correction and nonsimuhaneous acquisition between PET and CT lead to some PET-CT artifacts which interrupt the image interpretation and may cause false-positive or falsenegative diagnosis. This review will talk about these artifacts, analyze the causes and discuss the possible preventive measures.
2005, 29(5): 205-209.
Abstract:
PET-CT is a good modality for localization of the malignant lesions. It is superior to PET in the diagnosis, localization and guiding treatment for head and neck cancer. Possessing of the superiority of PET and CT, PET-CT can improves the accuracy and confidence for diagnosis and staging and helps to reliably distinguish malignant lesions from physiologic uptake and some inflammation. It is also helpful for guiding more accurate radiotherapy. Although PET-CT has a lot of superiorities, it still has some shortcomings in the diagnosis of the thyroid cancer, parotid gland tumor and in the discriminating malignancy from some active inflammation.
PET-CT is a good modality for localization of the malignant lesions. It is superior to PET in the diagnosis, localization and guiding treatment for head and neck cancer. Possessing of the superiority of PET and CT, PET-CT can improves the accuracy and confidence for diagnosis and staging and helps to reliably distinguish malignant lesions from physiologic uptake and some inflammation. It is also helpful for guiding more accurate radiotherapy. Although PET-CT has a lot of superiorities, it still has some shortcomings in the diagnosis of the thyroid cancer, parotid gland tumor and in the discriminating malignancy from some active inflammation.
2005, 29(5): 209-213.
Abstract:
Ovarian cancer is the leading cause of death among women with gynecologic malignancies, 18F-fluorodeoxyglucose (18SF-FDG) positron emission tomography (PET) is a well-established method for detecting, staging, cancer recurrence and therapeutic response and prognosis of ovarian cancer. PET-CT is helpful for the surgry guide and second-look laparotomy. Specific radiolabel pharmacies to ovarian cancer such as 124I-C6.5 diabody has been successfully imaged in animal with PET-CT.
Ovarian cancer is the leading cause of death among women with gynecologic malignancies, 18F-fluorodeoxyglucose (18SF-FDG) positron emission tomography (PET) is a well-established method for detecting, staging, cancer recurrence and therapeutic response and prognosis of ovarian cancer. PET-CT is helpful for the surgry guide and second-look laparotomy. Specific radiolabel pharmacies to ovarian cancer such as 124I-C6.5 diabody has been successfully imaged in animal with PET-CT.
2005, 29(5): 213-216.
Abstract:
18F-fluorodeoxyglucose (18F-FDG) PET or PET-CT can directly detect increased glucose metabolism of neoplastic cells nested in the skeleton, making it a sensitive method for assessment of bone metastases.
18F-fluorodeoxyglucose (18F-FDG) PET or PET-CT can directly detect increased glucose metabolism of neoplastic cells nested in the skeleton, making it a sensitive method for assessment of bone metastases.
2005, 29(5): 216-219,226.
Abstract:
PET imaging plays an important role in staging, restaging, evaluating the treatment effects and the prognosis of the lymphoma. PET-CT realized the fuse of functional and anatomic imaging in one gantry and showed more values in clinical diagnosis. It makes the location and characterization of the lesions more accurate.
PET imaging plays an important role in staging, restaging, evaluating the treatment effects and the prognosis of the lymphoma. PET-CT realized the fuse of functional and anatomic imaging in one gantry and showed more values in clinical diagnosis. It makes the location and characterization of the lesions more accurate.
2005, 29(5): 220-222.
Abstract:
Breast cancer is the most common malignancy in women in most of countries. During the past decades, the application of PET with 18F-fluoro-2-deoxy-D-glocuse (18F-FDG) has remarkably improved the managemant of breast cancer. Nevertheless, due to anatomical localisation of 18F-FDG uptake was difficult, the clinical interpretation of 18F-FDG PET scan could not be exactly. A novel combined PET-CT system has largely improved the capacity of sensitivity and specificity in the diagnosis of breast cancer. In this artiacal we focus on the application value of PET-CT to breast cancer diagnosis, with respect to dissease re-staging, treatment monitoring, preoperative staging and radiotherapy planning.
Breast cancer is the most common malignancy in women in most of countries. During the past decades, the application of PET with 18F-fluoro-2-deoxy-D-glocuse (18F-FDG) has remarkably improved the managemant of breast cancer. Nevertheless, due to anatomical localisation of 18F-FDG uptake was difficult, the clinical interpretation of 18F-FDG PET scan could not be exactly. A novel combined PET-CT system has largely improved the capacity of sensitivity and specificity in the diagnosis of breast cancer. In this artiacal we focus on the application value of PET-CT to breast cancer diagnosis, with respect to dissease re-staging, treatment monitoring, preoperative staging and radiotherapy planning.
2005, 29(5): 223-226.
Abstract:
The technology of PET had developed rapidly, and made it more and more important in stage and radiotherapy of tumor. The results of PET can give some biological information, such as the density of tumor and the sensitiveness to radiotherapy, these information together with the morphologic modalities, for example CT and MRI, offer a new opportunity to target the tumor cell in the therapy. Intensive Modulated Radiotherapy based on PET-CT, have the ability to display the biologic target through the fusion image of PET and CT, and create the concept of biologic target volume. In theory, within the high metabolic region of fluorideoxyglucose, you can apply a higher appropriate daily radiotherapy dose for better result. So the tumor diagnostic technology of PET-CT and IMRT bring a new biologic radiotherapy into reality.
The technology of PET had developed rapidly, and made it more and more important in stage and radiotherapy of tumor. The results of PET can give some biological information, such as the density of tumor and the sensitiveness to radiotherapy, these information together with the morphologic modalities, for example CT and MRI, offer a new opportunity to target the tumor cell in the therapy. Intensive Modulated Radiotherapy based on PET-CT, have the ability to display the biologic target through the fusion image of PET and CT, and create the concept of biologic target volume. In theory, within the high metabolic region of fluorideoxyglucose, you can apply a higher appropriate daily radiotherapy dose for better result. So the tumor diagnostic technology of PET-CT and IMRT bring a new biologic radiotherapy into reality.
2005, 29(5): 227-232.
Abstract:
18F-fluorodeoxyglueose (18F-FDG) is widely used to detect tumor with PET. However, 18F-FDG is not specific for tumor imaging because glucose is also utilized by other benign cells. 3'-deoxy-3'-18F-fluorothymi-dine (18F-FLT) is developed to overcome the limitations of 18F-FDG and to image cellular proliferation by PET. 18F-FLTfeatures an excellent proliferation tracerfor PET studies of tumors. The advantage of 18F-FLT is based on thymidine kinase-1 (TK 1) catalyzed phosphorylation of FLT and the intracellular accumulation of 18F-FLT is dependent on the presence of TK1, which is closely related to cellular proliferation in tumor cells undergoing DNA replication during the S phase of the cell cycle. Therefore, ISF-FLT is expected to be a feasible PET tracer for diagnosing, evaluating and monitoring the early response to therapy in oncology.
18F-fluorodeoxyglueose (18F-FDG) is widely used to detect tumor with PET. However, 18F-FDG is not specific for tumor imaging because glucose is also utilized by other benign cells. 3'-deoxy-3'-18F-fluorothymi-dine (18F-FLT) is developed to overcome the limitations of 18F-FDG and to image cellular proliferation by PET. 18F-FLTfeatures an excellent proliferation tracerfor PET studies of tumors. The advantage of 18F-FLT is based on thymidine kinase-1 (TK 1) catalyzed phosphorylation of FLT and the intracellular accumulation of 18F-FLT is dependent on the presence of TK1, which is closely related to cellular proliferation in tumor cells undergoing DNA replication during the S phase of the cell cycle. Therefore, ISF-FLT is expected to be a feasible PET tracer for diagnosing, evaluating and monitoring the early response to therapy in oncology.
2005, 29(5): 232-237.
Abstract:
18F-fluorodeoxyglucose(18F-FDG) was most wildly used radiopharmaxeuticals for tumors. It wasn't suitable for some malignant tumors because of it's normal biodistribution. We review some 11C labeled radiopharmaceuticals, including 11C-methionine, 11C-choline and 11C-acetate, for primary diagnosis and staging with brain tumors, head and neck cancer, lung cancer, liver tumors, gynecologic tumors, prostate cancer, bladder cancer, bone and soft tissue tumors, and the monitor value for radiotherapy. The 11C labeled radiopharmaceuticals were very important complement of 18F-FDG.
18F-fluorodeoxyglucose(18F-FDG) was most wildly used radiopharmaxeuticals for tumors. It wasn't suitable for some malignant tumors because of it's normal biodistribution. We review some 11C labeled radiopharmaceuticals, including 11C-methionine, 11C-choline and 11C-acetate, for primary diagnosis and staging with brain tumors, head and neck cancer, lung cancer, liver tumors, gynecologic tumors, prostate cancer, bladder cancer, bone and soft tissue tumors, and the monitor value for radiotherapy. The 11C labeled radiopharmaceuticals were very important complement of 18F-FDG.
2005, 29(5): 238-240,封三.
Abstract:
More than two decades of intense research have allowed gene therapy to move from the laboratory to the clinical setting, where its use for the treatment of human pathologies has been considerably increased in the last years. However, many crucial questions remain to be solved in this challenging field. In vivo imaging with positron emission tomography (PET) by combination of the appropriate PET reporter gene and PET reporter probe could provide invaluable qualitative and quantitative information to answer multiple unsolved questions about gene therapy. PET imaging could be used to define parameters not available by other techniques that are of substantial interest not only for the proper understanding of the gene therapy process, but also for its future development and clinical application in humans.
More than two decades of intense research have allowed gene therapy to move from the laboratory to the clinical setting, where its use for the treatment of human pathologies has been considerably increased in the last years. However, many crucial questions remain to be solved in this challenging field. In vivo imaging with positron emission tomography (PET) by combination of the appropriate PET reporter gene and PET reporter probe could provide invaluable qualitative and quantitative information to answer multiple unsolved questions about gene therapy. PET imaging could be used to define parameters not available by other techniques that are of substantial interest not only for the proper understanding of the gene therapy process, but also for its future development and clinical application in humans.
Submit
Author Login
Referees
Editor-in-Chief
Editor Center
Email alert
RSS
